#340 - AMA #69: Scrutinizing supplements: creatine, fish oil, vitamin D, and more—a framework for understanding effectiveness, quality, and individual need

Episode Summary

Executive Summary: This AMA sneak peek frames supplement use around a practical decision-making model: ask whether a supplement treats deficiency or aims for supra-normal levels, whether it supports lifespan or health span, whether benefits are measurable, how it works, and whether risk-reward and product quality justify use. Creatine is used as the main case study, showing strong evidence for short-burst performance and some cognitive promise, while broader supplementation remains highly individualized.

Main Topics: Framework for evaluating supplements (Priority: 5/5): Peter Attia outlines a five-part framework for assessing any supplement: deficiency vs supra-normal dosing, lifespan vs health span, measurable biomarkers, mechanism of action, and risk-reward including product quality. Supplements vs pharmaceuticals and regulation (Priority: 5/5): The discussion emphasizes that supplements are far less regulated than drugs, and that consumers should avoid ideological distinctions and instead assess any molecule by evidence, safety, and quality. Creatine as the primary case study (Priority: 5/5): Creatine is analyzed in depth as a supplement primarily used for performance and possibly cognition, with strong evidence for muscle-related benefits and low overall risk in appropriate users. Evidence, mechanisms, and biomarkers (Priority: 4/5): The episode explains how creatine supports ATP regeneration via phosphocreatine, why it helps short intense efforts, and why there is no practical biomarker for tissue creatine status in routine use. Special populations and practical cautions (Priority: 4/5): The speakers discuss possible benefits in women, potential relevance during hormonal transitions, and caution around pregnancy and people with imperfect kidney function. Supplement quality and formulation (Priority: 4/5): The episode highlights the importance of choosing pure, well-made products, especially in a market where quality control may be weaker than in pharmaceuticals.

Key Arguments: A useful supplement framework is more valuable than one-size-fits-all recommendations because supplement decisions are highly individualized. Consumers should not treat 'natural' supplements as categorically safer or better than pharmaceuticals; regulation and quality matter more than ideology. Creatine is mainly used to achieve supra-normal levels for performance, not to correct a typical deficiency. Creatine has its clearest benefits in high-intensity, burst-type activity and may modestly increase lean mass and power. There is emerging but not definitive evidence that creatine may help cognition and possibly recovery from injury. No routine biomarker exists for creatine adequacy; users generally follow standard dosing protocols instead. Creatine’s mechanism is well understood for muscle energy metabolism through phosphocreatine-mediated ATP regeneration. The overall risk-reward profile of creatine is favorable, but kidney disease and creatinine lab interpretation require caution. Women may derive particular benefit because they generally have lower creatine stores and may experience hormonal contexts where creatine demand is altered. Product purity matters: creatine monohydrate is the preferred form, and plain, filler-free products are recommended.

Data Points: Creatine dose: 3-5 grams per day - Typical maintenance dose said to fully maximize muscle stores. Older loading protocol: ~20 grams per day - Historical high-dose loading phase before maintenance dosing. Observed performance benefit: 5-15% - Range cited for improvements in muscle performance parameters such as power and hypertrophy. Cognition evidence base: 16 RCTs - A recent meta-analysis examining creatine’s effect on memory. Supplement risk tier: Low-risk, modest-reward - Attia’s summary characterization of creatine. Population caution: Anything but perfect kidney function - Patients with impaired renal function should discuss creatine use with their doctor and interpret creatinine labs carefully.

Pivotal Quotes: "I'm not trying to give you fish, I'm trying to make sure you know how to fish." — Peter Attia: Explains why the episode focuses on a decision framework rather than blanket supplement recommendations. "Our view is generally to approach this the way the kidney approaches the filtration of glucose, sodium, and potassium, which is you dump everything out and then ask the question, what should be added back in?" — Peter Attia: Describes the mental model for reviewing all supplements and medications. "Creatine really is the version to take." — Peter Attia: Reinforces that creatine monohydrate is the preferred formulation.

Implications: Listeners should evaluate supplements systematically rather than emotionally, prioritizing evidence, safety, biomarkers, and quality. Creatine emerges as one of the more defensible OTC options, while most other supplements still require individualized judgment.